Regression analysis was used to model trends in examination performance as a function of residency year.
INTRODUCTION AND OBJECTIVES:
The diagnostic management of men presenting for evaluation for prostate cancer can be challenging, particularly in those who are found to have a negative 12-core biopsy. Multi-parametric MRI (mpMRI) affords important information regarding suspicious lesions within the prostate that were previously unrecognized in the pre-MRI era. The aim of this study was to describe the negative predictive value of mpMRI in the detection of clinically significant prostate cancer for men undergoing evaluation for suspected prostate cancer.
METHODS: A retrospective analysis was performed on men who underwent mpMRI of the prostate with targeted biopsy and standard 12 core biopsy between January 2015 through July of 2018. PIRADs version 2 was utilized to identify lesions suggestive of underlying prostate cancer. All lesions with PI-RADs score greater than 3 were biopsied in a targeted fashion. Gleason scores from standard 12 core biopsies and targeted biopsies were included for analysis. For the purposes of this study, we defined clinically significant prostate cancer as Gleason score 7 or greater. Standard 12-core biopsy was considered the "gold standard" for comparative assessment. The negative predictive value of mpMRI with targeted biopsy was assessed.
RESULTS: A total of 592 men underwent mpMRI with targeted biopsy and concurrent standard 12 core biopsy. When compared to standard 12 core biopsy, mpMRI was found to have superior negative predictive value (92.3%; 95% CI: (89.8%-94.8%)) for men undergoing evaluation for prostate cancer. mpMRI with targeted biopsy was also more likely to detect clinically significant prostate cancer when compared to standard 12 core biopsy (27.5% vs 22.3%; p[0.002).
CONCLUSIONS: The negative predictive value of mpMRI provides useful insight in the assessment of men undergoing work up for prostate cancer. Utilization of the negative predictive value of mpMRI for clinically significant prostate cancer may reduce the unwanted detection of low risk prostate cancers.
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MP36-02 PERIPROCEDURAL AND DIAGNOSTIC OUTCOMES OF TRANSRECTAL VERSUS TRANSPERINEAL US/MRI GUIDED FUSION PROSTATE BIOPSY: MULTI-INSTITUTIONAL PROPENSITY SCORE MATCHED PAIR ANALYSIS
INTRODUCTION AND OBJECTIVES: Many software for fusion prostate biopsy (FPB) have been developed in the last years, most of them not providing the opportunity to combine transrectal (TR) and transperineal (TP) approach. Whereas one of these two approaches is beneficial in terms of complication rates or in terms of diagnostic accuracy is yet to be determined. The aim of this study was to compare periprocedural complication rates and diagnostic performance in propensity score matched pair cohorts to minimize the selection bias of non-random assignment of patients to TP as opposed to TR FPB.
METHODS: Baseline, periprocedural and pathologic data of 1197 patients who received FPB were prospectively collected in 7 different centers. TR approach was performed in most patients (1065, 89%, vs 132 TP). A 1:1 propensity score matched (PSM) analysis was employed to reduce covariate imbalances to <10%. The two selected PSM cohorts were compared for periprocedural and diagnostic performance. Chi-square or Fisher exact test and Student t test were used to compare categorical and continuous variables, respectively. Two-sided p values <0.05 were considered statistically significant. RESULTS: In the overall cohort, patients treated with TR-FPB had significantly lower number of target areas, of target, random and total number of cores, lower prostate volume, higher incidence of PIRADS 3 lesions and of previous negative prostate biopsy (all p values <0.001). After applying the PSM analysis, the two cohorts of
